Please upgrade your browser.
Preclinical studies have suggested that sunitinib accelerates metastases in animals, ascribing this to inhibition of the vascular endothelial growth factor receptor or the tumor’s adaptation.
Lpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics
The company is developing three drug candidates: iSONEP™ is being studied in a Phase 2 trial in wet AMD patients; ASONEP™ is being studied in a Phase 2 trial in renal cell carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in pain, neurotrauma, and other diseases.
AVEO Pharmaceuticals, Inc. (AVEO) and Astellas Pharma, Inc. (ALPMY) recently announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review tivozanib on May 2, 2013.
Live day-long kidney health web chat at KidneyCancer.org
The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement.
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced it has validated the durability of the immune response for metastatic renal cell carcinoma (mRCC) patients treated with AGS-003.
Big Pharma companies have hit a wall chasing billion-dollar drugs. Novartis CEO Joseph Jimenez outlines a new paradigm for blockbuster medications.
India's patent appeals body Monday rejected Bayer AG's (BAYRY, BAYN.XE) plea to stop a local company from manufacturing and selling a generic version of its cancer drug Nexavar, a ruling that has wider implications for multinational drug makers operating in the South Asian nation.
New insight into grape seed extract as a therapeutic and preventative measure to fight obesity-induced kidney damage is presented in a new study.
The studentship benefits include a bursary of £18,000 pa, University & College fees (home/EU rate only) and the opportunity to work in a cutting edge research environment.
|NeonCRM by Neon One|